

Eiki Ichihara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3815847/publications.pdf>

Version: 2024-02-01

87
papers

2,060
citations

279798

23
h-index

254184

43
g-index

90
all docs

90
docs citations

90
times ranked

3172
citing authors

#	ARTICLE	IF	CITATIONS
1	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK ⁺ positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	30.7	245
2	Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell ⁺ like Properties in Cancer Cells. <i>Cancer Research</i> , 2013, 73, 3051-3061.	0.9	241
3	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non ⁺ Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 273-279.	1.1	119
4	Non ⁺ Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases. <i>Cancer Research</i> , 2016, 76, 1506-1516.	0.9	115
5	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. <i>Cancer Research</i> , 2017, 77, 2990-3000.	0.9	106
6	Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non ⁺ Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001. <i>Journal of Thoracic Oncology</i> , 2015, 10, 486-491.	1.1	93
7	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 140-145.	2.0	68
8	Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systemic Review. <i>PLoS ONE</i> , 2011, 6, e26646.	2.5	66
9	Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation <i>in vivo</i> . <i>Cancer Research</i> , 2009, 69, 5091-5098.	0.9	65
10	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 589-597.	4.1	62
11	Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non ⁺ Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. <i>Clinical Lung Cancer</i> , 2018, 19, e5-e9.	2.6	44
12	The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 762-765.	1.3	43
13	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. <i>Respiratory Investigation</i> , 2019, 57, 512-533.	1.8	36
14	Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor ⁺ mutated lung cancer model. <i>Cancer Science</i> , 2013, 104, 1440-1446.	3.9	34
15	MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. <i>Scientific Reports</i> , 2018, 8, 1955.	3.3	34
16	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non ⁺ small-cell lung cancer differ based on PD-L1 expression. <i>European Journal of Cancer</i> , 2021, 149, 73-81.	2.8	34
17	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. <i>European Respiratory Journal</i> , 2022, 60, 2200380.	6.7	34
18	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 140-146.	2.0	32

#	ARTICLE	IF	CITATIONS
19	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864.	3.9	29
20	Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2013, 81, 435-439.	2.0	28
21	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	1.8	28
22	Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 29525-29531.	1.8	28
23	Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. <i>International Journal of Clinical Oncology</i> , 2016, 21, 81-87.	2.2	26
24	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 101-106.	4.2	26
25	Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small cell lung cancer: KEYNOTE-189 Japan Study. <i>Cancer Science</i> , 2021, 112, 3255-3265.	3.9	26
26	Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2009-2018.	1.1	22
27	Targeting angiogenesis in cancer therapy. <i>Acta Medica Okayama</i> , 2011, 65, 353-62.	0.2	22
28	Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. <i>Cancer Science</i> , 2018, 109, 3149-3158.	3.9	20
29	Utility of immune checkpoint inhibitors in non-small cell lung cancer patients with poor performance status. <i>Cancer Science</i> , 2020, 111, 3739-3746.	3.9	20
30	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 1031-1038.	2.3	18
31	Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 458-464.	1.3	17
32	The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e20601-e20601.	1.6	17
33	Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 360-367.	2.1	15
34	Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 54-58.	2.0	15
35	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 163-167.	0.7	14
36	Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1447-1453.	1.3	14

#	ARTICLE	IF	CITATIONS
37	Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 786-788.	1.3	13
38	A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 963-968.	1.3	11
39	Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 251-256.	2.3	11
40	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605.	2.6	10
41	Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations. <i>Biochemical and Biophysical Research Communications</i> , 2020, 532, 341-346.	2.1	10
42	CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in EGFR-Mutant Lung Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 1111-1126.	3.4	10
43	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. <i>Clinical Lung Cancer</i> , 2017, 18, 241-244.	2.6	9
44	Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, e168-e169.	1.1	9
45	Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B). <i>International Journal of Clinical Oncology</i> , 2022, 27, 112-120.	2.2	9
46	Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol. <i>Clinical Lung Cancer</i> , 2017, 18, 245-249.	2.6	8
47	Identification of targetable kinases in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2022, 23, 20.	3.6	8
48	Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 279-286.	1.3	7
49	Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 101-108.	1.1	7
50	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662.	4.1	7
51	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1139-1144.	2.2	7
52	Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 941-947.	2.3	6
53	Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 434-437.	1.3	6
54	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3749-3755.	2.5	6

#	ARTICLE	IF	CITATIONS
55	A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant <i>EGFR</i> and activated IGF1R. Japanese Journal of Clinical Oncology, 2021, 51, 956-965.	1.3	6
56	A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer, 2017, 112, 188-194.	2.0	5
57	Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. International Journal of Clinical Oncology, 2019, 24, 41-45.	2.2	5
58	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). Clinical Lung Cancer, 2020, 21, e592-e596.	2.6	5
59	Granulation Tissue-induced Pseudo-relapse During Nivolumab Treatment in Advanced Non-small Cell Lung Cancer. In Vivo, 2019, 33, 2113-2115.	1.3	4
60	Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Acta Medica Okayama, 2017, 71, 453-457.	0.2	4
61	Comparison of bronchoscopy and computed tomography-guided needle biopsy for re-biopsy in non-small cell lung cancer patients. Respiratory Investigation, 2021, 59, 240-246.	1.8	3
62	Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies. Respiratory Investigation, 2019, 57, 460-465.	1.8	2
63	Patients' preferences and perceptions of lung cancer treatment decision making: results from Okayama lung cancer study group trial 1406. Acta Oncologica, 2020, 59, 324-328.	1.8	2
64	The effect and safety of an immune checkpoint inhibitor rechallenge in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21147-e21147.	1.6	2
65	Rapid Disease Progression of Advanced Non-small Cell Lung Cancer Five Months after Cessation of Pembrolizumab. Acta Medica Okayama, 2020, 74, 423-425.	0.2	2
66	Three doses of mRNA COVID-19 vaccine protects from SARS-CoV-2 infections in Japan. Journal of Internal Medicine, 2022, 292, 687-689.	6.0	2
67	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	1.7	2
68	Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan. Internal Medicine, 2022, 61, 379-383.	0.7	1
69	Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR mutant lung cancer with HIF1 α /TGF β 1 expression. Oncology Letters, 2021, 22, 639.	1.8	1
70	Impact of body surface area on efficacy of gefitinib in patients with non-small cell lung cancer harboring activating epidermal growth factor receptor mutation.. Journal of Clinical Oncology, 2012, 30, 2607-2607.	1.6	1
71	Crizotinib to overcome alectinib-resistance in non-small cell lung cancer (NSCLC) harboring EML4-ALK.. Journal of Clinical Oncology, 2015, 33, e19140-e19140.	1.6	1
72	Randomized phase II study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in advanced non-small cell lung cancer: The OLCSG1406 trial.. Journal of Clinical Oncology, 2019, 37, e23105-e23105.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Association between Histological Types and Enhancement of Dynamic CT for Primary Lung Cancer. <i>Acta Medica Okayama</i> , 2020, 74, 129-135.	0.2	1
74	Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, e79.	1.1	0
75	A Case of Lung Cancer That Showed an Abscopal Effect After Irradiation of Simultaneous Oropharyngeal Cancer. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 109-112.	0.1	0
76	Impact on second-line treatment after failure of immune checkpoint inhibitor (ICI) combination chemotherapy in extensive-disease small cell lung cancer: Experience of the Okayama Lung Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2021, 39, e20590-e20590.	1.6	0
77	Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression. <i>European Journal of Cancer</i> , 2021, 157, 523-524.	2.8	0
78	Survival post-progression (SPP) in phase III trials of chemotherapy in advanced NSCLC: Its potentially different impact on OS in the first-line and salvage settings. <i>Journal of Clinical Oncology</i> , 2012, 30, e18027-e18027.	1.6	0
79	Difference in incidence and pattern of salvage treatment after failure to first-line epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy and standard cytotoxic chemotherapy in pts with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: Okayama Lung Cancer Study Group experience. <i>Journal of Clinical Oncology</i> , 2012, 30, 7576-7576.	1.6	0
80	Impact of body surface area (BSA) on efficacy of gefitinib in patients with non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2013, 31, e19167-e19167.	1.6	0
81	Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2014, 32, e19102-e19102.	1.6	0
82	Second primary cancer in survivors of locally advanced NSCLC treated with concurrent chemoradiation followed by surgery. <i>Journal of Clinical Oncology</i> , 2016, 34, 10100-10100.	1.6	0
83	Association with consolidation chemotherapy after concurrent chemoradiotherapy followed by surgery and the disease free survival in patients with stage III non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2016, 34, e20053-e20053.	1.6	0
84	Chemoradiotherapy (CRT) for locally-advanced (LA) lung cancer patients with interstitial lung abnormalities (ILA). <i>Journal of Clinical Oncology</i> , 2017, 35, e20057-e20057.	1.6	0
85	Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2018, 36, e21034-e21034.	1.6	0
86	An Update on Targeted Therapy in Advanced Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 377-382.	0.1	0
87	Preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: An open-label, randomized, phase II study. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS12141-TPS12141.	1.6	0